Pfizer invests in Homology and adds to its gene therapy ambitions

Pfizer is making a $60 million equity investment in the gene therapy company Homology Medicines, betting on what one of its rare disease executives termed a “potentially transformational” therapeutic option for patients with a rare metabolism disorder known as phenylketonuria, or PKU.